CBER chief on remote work, CRISPR-Cas9, and rare disease gene therapy accelerated approval guidance
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)North AmericaProduct developmentRegulatory Intelligence/PolicyResearch, Design and Development